Theriva (TOVX) raises ~$4.4M via warrant exercise at $0.54/share; grants 16.2M new warrants

Theriva Biologics, Inc.

Entered warrant inducement with existing holders exercising 8,092,280 shares at $0.54 for ~$4.4M gross proceeds.
Issued new warrants for 16,184,560 shares (200% of exercised) at same $0.54 exercise price, exercisable 5 years from stockholder approval.
Net proceeds will be used for working capital; AGP served as financial advisor with 7% cash fee.
New warrants and underlying shares issued in private placement under Section 4(a)(2); resale registration to be filed within 30 days.
Company must seek stockholder approval for exercise of new warrants; meetings every 60 days if not obtained.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Theriva Biologics, Inc. issued 16,184,560 shares of Common Stock of warrant to certain holders of existing warrants for cash exercise of existing warrants at $0.54 per share for aggregate gross proceeds of approximately $4.4 million.

Security: warrant
Shares: 16,184,560 shares of Common Stock
Purchaser: certain holders of existing warrants
Consideration: cash exercise of existing warrants at $0.54 per share for aggregate gross proceeds of approximately $4.4 million

Exact text from the filing

Warrants, the “Existing Warrants”). Pursuant to the Inducement Agreement, (1) the Holders agreed to exercise for cash the Existing Warrants at a reduced exercise price of $0.54 per share and (2) the Company agreed to issue to the Holders new Common Stock Purchase Warrants to purchase up to an aggregate of 16,184,560 shares of Common Stock (the “New

View on SEC.gov

Browse all equity issuances →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-100468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.